Am J Transplant, Volume 19, Suppl 3 Archives - Page 174 of 214 - ATC Abstracts

2019 American Transplant Congress
Recipient Myeloid Notch1 Disruption Shifts Neutrophil towards Anti-Inflammatory Phenotype and Protects Liver Grafts from Ischemia-Reperfusion Injury
S. Kageyama¹, H. Hirao¹, K. Kadono¹, K. Nakamura¹, K. J. Dery¹, T. Ito², D. Oncel¹, J. Aziz¹, B. Ke¹, F. M. Kaldas², R. W. Busuttil², J. W. Kupiec‐Weglinski¹
¹Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA, ²Surgery, Ronald Reagan UCLA Medical Center, UCLA, Los Angeles, CA
*Purpose: Liver ischemia-reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and predisposes to rejection crises in orthotopic liver transplantation (OLT). We…
2019 American Transplant Congress
Bisphosphonates Effectively Improve the Long Term Renal Transplant Outcomes; A Single Center Retrospective Study
S. Song¹, K. Huh², H. Choi³, J. Lee², D. Kim², Y. Kim², M. Kim², S. Kim², D. Joo², B. Kim³
¹Surgery, Ewha Womans University, Seoul, Korea, Republic of, ²Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Kidney transplantation (KT) is a treatment of choice for patients with end-stage renal disease. Despite of remarkable improvement in short term graft survival, few…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Late Acute Rejection Increases Risk Of Graft Failure In Ldlt Recipients: Data From The A2all Cohort
H. J. Braun, J. L. Dodge, J. D. Grab, S. M. Syed, G. R. Roll, C. E. Freise, J. P. Roberts, N. L. Ascher
University of California, San Francisco, San Francisco, CA
*Purpose: Late acute rejection (LAR) is defined as an initial episode of acute rejection occurring >6 months after transplantation. LAR in liver transplantation (LT) is…
2019 American Transplant Congress
One Study: A Consortium Model of Clinical Trials Optimized for Comparing New Immune Therapies via Centralized Immune Monitoring
B. Sawitzki¹, S. Schlickeiser¹, M. Streitz¹, K. Jürchott¹, J. Hutchinson², E. Geissler², P. Investigators³
¹Charite Universitätsmedizin, Berlin, Germany, ²University of Regensburg, Regensburg, Germany, ³ONE Study Consortium, EU, Germany
*Purpose: Immune regulatory cell subpopulations can potentially control immune responses to allow immunosuppression (IS) drug minimization. In the ONE Study, an EU FP7-funded research group…
2019 American Transplant Congress
Prevention of Graft Ischemia-Reperfusion Injury in Ischemia-Free Liver Transplantation
Z. Guo, X. He, Q. Zhao, S. Huang, Z. Zhang, L. Wang, W. Ju, G. Chen
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Graft ischemia-reperfusion injury (IRI) is an inevitable event in organ transplantation, which often leads to a number of complications and even patient deaths. We…
2019 American Transplant Congress
Does the Type of Pre-Heart Transplant Desensitization Therapy Affect 5-Year Post-Transplant Outcomes?
J. Patel, E. Kransdorf, R. Levine, S. Dimbil, L. Czer, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: As many patients with severe heart disease require mechanical circulatory support (MCS), the number of sensitized patients developing circulating antibodies continues to rise. In…
2019 American Transplant Congress
Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients
J. Ekberg¹, S. Baid-Agrawal¹, B. Jespersen², R. Källén³, E. Rafael³, K. Skov², P. Lindnér¹
¹Institute of Clinical Sciences, Transplant Institute, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Nephrology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Transplantation, Skane University Hospital, Malmoe, Sweden
*Purpose: Comparison of two immunosuppressive protocols, steroid-free with antithymocyte globulin (ATG) induction, and steroid containing with basiliximab induction, regarding the incidence of PTDM, one year…
2019 American Transplant Congress
Preemptive Kidney Transplantation: Is There a Role for ABO Incompatible Transplantation?
M. N. Mustian¹, B. A. Shelton¹, P. A. MacLennan¹, R. D. Reed¹, G. McGwin¹, B. J. Orandi¹, D. Sawinski², V. Kumar¹, J. E. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA
*Purpose: Barriers to kidney transplantation (KT) exist, including ABO incompatibility (ABOi) between potential living kidney donors and transplant candidates. Incompatible pairs can undergo desensitization or…
2019 American Transplant Congress
Utilization of DCD Donors >50 Years Old for Liver Transplantation
T. Chaly, K. Hoidal, C. Cashman, J. Brink, A. Mehrotra, W. Van der Werf
Arizona Transplant Associates, PC, Phoenix, AZ
*Purpose: End stage liver disease is becoming more prevalent in the United States with approximately 4.9 million adults carrying the diagnosis. It is estimated that…